NCT02795858View on ClinicalTrials.gov

A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 14, 2016

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2023

Conditions

Carcinoid Tumors

Interventions

DRUG

Ramucirumab

DRUG

Somatostatin Analog

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02795858 - A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors | Biotech Hunter | Biotech Hunter